PURPOSE The Overactive Bladder Innovative Therapy Trial during phase 1 was a randomized trial demonstrating comparable effectiveness of percutaneous tibial nerve stimulation and extended-release tolterodine during 12 weeks of therapy for frequency, nocturia, urgency, voided volume and urge incontinence episodes. In this second phase of the Overactive Bladder Innovative Therapy Trial we assessed...

Although some urogenital drugs such as tamsulosin or tolterodine have reached blockbuster status, the pharmacotherapy of urogenital disorders has been lagging behind many other therapeutic areas for a long time. Malformations and trauma of the urogenital tract are a clear domain of surgery, and malignant urogenital disease has more in common with malignancies of other tissues than with other ur...

BACKGROUND Pharmacotherapy constitutes an important adjunct to behavioral therapy for the treatment of overactive bladder (OAB). Tolterodine and oxybutynin are commonly prescribed drugs for OAB treatment that exert their beneficial effect by suppressing bladder muscle contractions. However, high discontinuation rates have been observed for these drugs in clinical trials, as well as in real-worl...